Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | BACH1 | O14867 | 1/20 | 0.31 |
| ▸ | MAFK | O60675 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinimide SCHEMBL14977585 | 0.85 | CYP1A2 (0.46) | CYP1A2CYP2D6CRBN | |
| SCHEMBL4798477 | 0.82 | CYP1A2 (1.00) | CYP1A2CYP2D6BACH1MAFK | |
| SCHEMBL1372 | 0.82 | CYP1A2 (1.00) | CYP1A2CYP2D6BACH1MAFK | |
| Hydrochloric Acid SCHEMBL1595766 | 0.80 | CYP1A2 (0.96) | CYP1A2CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL21805838 | 0.80 | CYP1A2 (0.96) | CYP1A2CYP2D6 | |
| SCHEMBL2645833 | 0.80 | CYP1A2 (0.96) | CYP1A2CYP2D6 | |
| SCHEMBL2597843 | 0.80 | CYP1A2 (0.96) | CYP1A2CYP2D6 | |
| Bromide SCHEMBL22418547 | 0.80 | CYP1A2 (0.96) | CYP1A2CYP2D6 | |
| Iodide SCHEMBL660783 | 0.80 | CYP1A2 (0.96) | CYP1A2CYP2D6 | |
| Water SCHEMBL1475933 | 0.80 | CYP1A2 (0.96) | CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10036004-B1 | Production of high purity chondroitinase ABC | ADVANTEK SERUM LABORATORIES LTD (HK) | 2018-07-31 | — | — | US | claimed |
| US-11529316-B2 | Ultrafine nanoparticles as multimodal contrast agent | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2022-12-20 | — | — | US | disclosed |
| CN-115472412-A | Method for preparing epoxy group magnetic ball based on glycidyl methacrylate and application | 武汉大学 | 2022-12-13 | — | — | CN | disclosed |
| US-20200108155-A1 | ULTRAFINE NANOPARTICLES AS MULTIMODAL CONTRAST AGENT | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2020-04-09 | — | — | US | disclosed |
| CN-110913909-A | Method for treating tumors | NH阿吉克斯治疗公司 | 2020-03-24 | — | — | CN | disclosed |
| US-20180327735-A1 | Production of high purity chondroitinase ABC | Advantek Serum Laboratories Ltd. (HK) | 2018-11-15 | — | — | US | disclosed |
| US-10036004-B1 | Production of high purity chondroitinase ABC | ADVANTEK SERUM LABORATORIES LTD (HK) | 2018-07-31 | — | — | US | disclosed |
| US-9796970-B1 | Production of high purity chondroitinase ABC | Advantek Serum Laboratories Ltd. (HK) | 2017-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200108155-A1 | ULTRAFINE NANOPARTICLES AS MULTIMODAL CONTRAST AGENT | PFN1, MKI67, FSCN1 | CYP1A2 4392/4885CYP2D6 4623/4885CRBN 2442/4885 |
| US-11529316-B2 | Ultrafine nanoparticles as multimodal contrast agent | PFN1, MKI67, FSCN1 | CYP1A2 4392/4885CYP2D6 4623/4885CRBN 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.